Wilmington Savings Fund Society FSB Has $502,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Wilmington Savings Fund Society FSB raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 3,676 shares of the company’s stock after acquiring an additional 343 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Neurocrine Biosciences were worth $502,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at $236,000. Plato Investment Management Ltd increased its holdings in Neurocrine Biosciences by 2,481.9% during the third quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after buying an additional 10,548 shares during the last quarter. Swiss National Bank increased its holdings in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after buying an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $3,236,000. Finally, KBC Group NV raised its holdings in shares of Neurocrine Biosciences by 78.3% in the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares during the period. 92.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on NBIX. Guggenheim dropped their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a report on Monday. HC Wainwright cut their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Barclays raised their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research report on Monday, December 23rd. StockNews.com raised shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They set a “hold” rating and a $138.00 price objective for the company. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $166.90.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $116.85 on Wednesday. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a market capitalization of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33. The stock’s fifty day moving average is $138.66 and its 200 day moving average is $131.23.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Equities research analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the sale, the chief executive officer now directly owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matt Abernethy sold 1,283 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total transaction of $196,132.21. Following the sale, the chief financial officer now directly owns 32,681 shares in the company, valued at $4,995,944.47. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 222,693 shares of company stock worth $32,718,279 over the last three months. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.